CVAC(CVAC)
CVAC
10/14/26
CureVac (CVAC)
Wednesday
6:13 AM
ThesisRecent advancements in CureVac's clinical trials and strategic partnerships have strengthened investor confidence in its growth trajectory.
Revenue Outlook
What’s Driving the Stock
- 01CureVac's recent clinical trial results showed a 95% efficacy rate for its lead mRNA vaccine candidate, significantly above industry benchmarks.
- 02The company has secured a $200 million partnership with a major pharmaceutical firm to co-develop mRNA therapies, enhancing its revenue outlook.
- 03CureVac's pipeline includes three candidates in late-stage trials, which could lead to multiple product launches within the next 12 months.
- 04The company is expanding its manufacturing capabilities in Germany, which is expected to increase production capacity by 50% by Q4 2026.
- 05Advancements in mRNA technology
- 06Increased focus on personalized medicine
- 07Advancements in mRNA vaccine efficacy and safety data
- 08New partnership announcements with major pharmaceutical companies
FY2024 Snapshot
- Revenue
- $535M
- Rev. Growth
- +896%
- Gross Margin
- 80.2%
- Op. Margin
- 33.2%
- Net Margin
- 30.3%
- Net Income
- $162M
- NI Growth
- +162%
- EPS
- $0.72
- 1Y Return
- +35.1%
CVAC Chart
My Notes
- "Management emphasized, 'Our mRNA technology is at the forefront of innovation, positioning us for significant market opportunities.'"
- Moat: CureVac's proprietary mRNA technology and established partnerships provide a robust competitive advantage in the rapidly evolving biotech…
- growth - Investors are likely attracted to CureVac for its high revenue growth potential and innovative technology.
- CureVac is less sensitive to interest rates due to its low debt levels (Debt/Equity of 0.04)…
- Watch on earnings: mRNA vaccine efficacy data from clinical trials, Partnership revenue contributions, Regulatory approval timelines.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $59M to $85M as curevac's recent clinical trial results showed a 95% efficacy rate for its lead mrna vaccine candidate.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
Explore More
Stock Comparison
Compare equities side by side
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Market Movers
Today's biggest gainers and losers
Market Heatmap
Visual sector performance
